EFL026
Join host Dr. Chase Hendrickson, Vanderbilt Unviersity Medical Center, as he discusses a recent Journal of the Endocrine Society (JES) article with Dr. Imali Sirisena, Program Director at Temple University, and Dr. Mike Tuttle, Chief of the Endocrinology Service at Memorial Sloan Kettering Cancer Center. The article featured this month is from the March 2022 edition of JES, “Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for 131I Administration.”
Meet the Speakers
R. Michael Tuttle, MD, is an Endocrinologist, Professor of Medicine, and Chief of the Endocrinology Service at Memorial Sloan Kettering Cancer Center in New York. He designed and validated the first real time risk assessment model for thyroid cancer management in which individual risk estimates are modified over time as a function of response to initial therapy. His research continues to center on important management aspects of thyroid cancer including efforts to better define (1) the risk of recurrence and death from thyroid cancer for individual patients, (2) the role of active surveillance in properly selected patients with low-risk papillary thyroid cancer, and (3) the proper application of minimalistic management options to better tailor the intensity of therapy and follow-up to the risks of undesirable outcomes. His clinical practice is entirely devoted to the evaluation and management of patients with thyroid cancer.
Imali Sirisena, MD, is Assistant Professor of Endocrinology at the Lewis Katz School of Medicine at Temple University in Philadelphia. A native of North Carolina, she completed medical school at New York Medical College and internal medicine residency at Montefiore Medical Center in Bronx, NY. She completed endocrinology fellowship at the University of Pennsylvania in 2015. Dr. Sirisena currently serves as Program Director for the endocrine fellowship program, and is active in pre-clerkship medical school education.
Resources
